Victoria has a long and rich relationship with the Europe, built on a history of migration, trade, investment and long established cultural ties. As major source markets for direct investment to Victoria, the major economies of Western Europe (Germany, France, Italy, Spain and the Netherlands) are also significant markets for the medical technology and biotechnology sectors and for Victorian pharmaceutical products and digital technologies.
Companies looking to Europe have almost 28 different markets from which to choose. While many companies look to key destinations such as Germany, France and the UK, there is an emerging trend to target smaller markets such as Scandinavia and Switzerland, for initial European market entry.
This BioBreakfast session will feature presentations and discussion on European:
• Commercial opportunities
• Market strategies
• Regulatory frameworks
• Business processes
• Barriers to entry and
• Risk management approaches
Who should attend?
Product development scientists and engineers; business development managers; sales and marketing executives; regulatory managers.
Date: Tuesday 21st March 2017
Time: Registration from 7:15am for a 7.30am networking breakfast followed by presentations and discussion from 8.00am – 9:00am
Venue: The Cube, ACMI, Federation Square, Melbourne
(Prices include GST)
To check if your organisation is a member, click here
Full refund given up to 7 days prior to the event
No refunds within 7 days of the event
John has extensive international business experience as Managing Director and Chief Executive Officer in public listed companies and private equity businesses operating in Australia, the UK, Europe, Asia and the US. His experience covers pharmaceutical and medical equipment manufacturing and distribution, finance, and FMCG businesses. He has a proven and significant track record of delivering continuous improvement and outstanding results.
John is the Chief Executive Office of MDI, a leading Australian pharmaceutical and medical device company specialising in emergency medicine solutions. MDI manufactures and distributes Penthrox, an iconic analgesic product as well as world leading asthma devices, oxygen therapies and other emergency medical equipment.
Nicoletta Muner GAICD, Global Director, Regulatory Affairs, Clinuvel Pharmaceuticals Ltd
Nicoletta has over 18 years’ experience in the pharmaceutical industry, where she had exposure to the entire drug development process, from raw material sourcing to analytical and manufacturing process development to non-clinical and clinical studies.
As a Regulatory Affairs professional she has mostly focused on the introduction of novel medicinal products, ranging from complex generics to biosimilars to new chemical entities, into international markets.
As the Global Director of Regulatory Affairs at Clinuvel Ms Muner has played a central role in obtaining multiple orphan drug designations for afamelanotide, acceptance of the Investigational New Drug (IND) application by the US Food and Drug Administration (FDA) and in the regulatory process which led to the European marketing authorisation of SCENESSE®.
Pierre’s 25-years of experience has been focused on bringing medtech and biotech innovations to the global markets. Before relocating in Australia, he had operated in a pan-European capacity for both the medical and diagnostic divisions of Fortune 500 Becton Dickinson.
In this position, Pierre was involved in five go-to-market cycles, from the initial product concept up to the “ready to launch” stage – including writing business plans, organising due diligence processes, setting up financial reporting processes and recruiting the operational teams across various countries in Europe.
Jefferson Harcourt, Director, Grey Innovation
Jefferson Harcourt formed Grey Innovation in 1998, and since its inception, Grey has undertaken engineering development work for a wide range of industry sectors. The Grey Innovation Group has a portfolio of companies in the MedTech, Environmental and Security fields.
Jefferson works with the research and investment community to help build business, sits on a number of start-up company boards, and is committed to helping create successful high-tech companies.